54 studies found for:    MACULAR DYSTROPHY, RETINAL, 3
Show Display Options
Rank Status Study
1 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
2 Active, not recruiting Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Dietary Supplement: Omega-3 fatty acid
3 Recruiting Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
4 Enrolling by invitation Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
Condition: Age-related Macular Degeneration
Interventions: Drug: Omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3;   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
5 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
6 Completed
Has Results
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
7 Unknown  DHA Supplementation in Patients With STGD3
Condition: Dominantly Inherited Stargardt's Disease (STGD3)
Intervention: Dietary Supplement: Over the counter DHA/EPA dietary supplementation
8 Completed Omega-3-fatty Acids on Age-related Macular
Condition: Aged Macular Degeneration
Interventions: Dietary Supplement: Omega 3;   Other: Olive Oil
9 Completed Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate 15 mg sterile suspension;   Other: Photodynamic Therapy (PDT)
10 Recruiting A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
11 Recruiting A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
12 Not yet recruiting A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: bevacizumab or aflibercept;   Drug: E10030 sham intravitreal injection
13 Completed Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment
Condition: Age-related Macular Degeneration
Intervention: Other: Nutritional study
14 Completed Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Condition: Macular Degeneration
Intervention: Drug: Lutein
15 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
16 Completed Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
Condition: Age-related Macular Degeneration
Intervention: Procedure: Aqueous sample
17 Completed
Has Results
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
Conditions: Macular Edema;   Diabetic Mellitus;   Retinal Disease
Interventions: Drug: pegaptanib sodium;   Other: sham injection
18 Completed A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
Condition: Neovascular Age-related Macular Degeneration
Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein
19 Completed
Has Results
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
Condition: Age Related Macular Degeneration
Intervention: Drug: CGC-11047
20 Completed
Has Results
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Condition: Exudative Age-related Macular Degeneration.
Interventions: Dietary Supplement: Anti-VEGF plus AREDS-2;   Dietary Supplement: Anti-VEGF plus AREDS-1

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years